• Northwest Biotherapeutics entered a USD 4.9 million convertible Promissory Note financing with YA II PN, a Yorkville-managed fund, on July 29, 2026.
• 12-month term. No payments due until maturity. 5% original issue discount. No interest.
• Note is convertible at the holder’s option at a small discount to the prevailing market price.
• Yorkville received a warrant to buy up to USD 2 million of shares at USD 0.21 per share.
• Standby equity subscription agreement allows up to USD 50 million share purchases over 24 months once the note is repaid or converted.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Northwest Biotherapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-089293), on July 31, 2026, and is solely responsible for the information contained therein.